trans-alpha-Bisabolene is an (E)-configured sesquiterpene hydrocarbon that shows up as a minor-to-moderate component in selected essential oils such as basil methyl-chavicol type and spike lavender. Compared with better-studied terpenes, the live evidence trail here is thin and weighted toward identity, occurrence, and volatile-ecology or biosynthesis context rather than direct isolate-level pharmacology. For AromaForge, it is most accurate to present trans-alpha-Bisabolene as a composition marker with limited constituent-specific evidence and explicit gaps around human safety and therapeutic relevance.
Chemical identity and composition
PubChem identifies trans-alpha-Bisabolene as C15H24 and distinguishes it from cis-alpha-bisabolene by the (E) side-chain geometry. In the archive it is already linked to basil ct. methyl chavicol and spike lavender source documents, where it appears as a low-percentage sesquiterpene companion rather than a dominant marker.
Aroma and practical use
- Use the recorded woody, spicy, green, resinous, resin descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
An open-access barley-fungal interaction study reported trans-alpha-Bisabolene among volatile compounds emitted during soil-root-pathogen interactions.
The abstract describes newly emitted terpene-rich volatile signatures during interactions between barley roots and pathogenic fungi; the full article's GC-MS tables include trans-alpha-Bisabolene in that volatile dataset.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Archive source documents place trans-alpha-Bisabolene at 1.9% in basil ct. methyl chavicol and 0.4-2.5% in spike lavender.
These GC-MS sources support the constituent as a real but secondary archive marker in selected aromatic herbs rather than a dominant identity driver.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedNo public IFRA limit, RIFM monograph, or constituent-specific human tolerability study was located for isolated trans-alpha-Bisabolene.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
The available literature is too sparse to support strong isolate-level benefit or safety conclusions beyond general sesquiterpene exposure context.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Mixture-level activity from oils containing trans-alpha-Bisabolene should not be translated into direct medical or performance claims for the isolated constituent.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
volatile emission during root-pathogen interaction
A barley-pathogenic-fungi interaction study identified trans-alpha-Bisabolene among emitted volatile compounds during below-ground interaction, supporting an ecological volatile-emission role rather than a human pharmacology mechanism.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- This pass did not locate a strong constituent-specific pharmacology paper for isolated trans-alpha-Bisabolene.
- No constituent-specific public dermal, sensitization, or phototoxicity threshold was verified.
- The trans isomer has materially less accessible literature than cis-alpha-bisabolene, so mechanism and benefit framing must stay conservative.
- Second-pass verification (2026-07-13): searched IFRA Standards Library and RIFM database by CAS 25532-79-0; only found RIFM monographs for the distinct compounds bisabolene (CAS 495-62-5) and alpha-bisabolol (CAS 515-69-5), not this specific (E)-alpha-bisabolene isomer. No IFRA standard specific to CAS 25532-79-0 located. dermal_limit_pct and sensitizing remain unverified estimates; left unchanged.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.